• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012 Product Image

Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012

  • ID: 2366290
  • December 2012
  • 40 pages
  • Global Markets Direct

Pre-Diabetes/Impaired Glucose Tolerance – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pre-Diabetes/Impaired Glucose Tolerance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pre-Diabetes/Impaired Glucose Tolerance. Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pre-Diabetes/Impaired READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Pre-Diabetes/Impaired Glucose Tolerance Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pre-Diabetes/Impaired Glucose Tolerance 7
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics under Development by Companies 9
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Products under Development by Companies 13
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Development 15
Resverlogix Corp. 15
Limerick BioPharma, Inc. 16
Pre-Diabetes/Impaired Glucose Tolerance – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
RVX-208 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
vildagliptin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
pioglitazone hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
sildenafil citrate - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
rosiglitazone maleate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LIM-0705 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Drug Profile Updates 30
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics - Dormant Products 33
Pre-Diabetes/Impaired Glucose Tolerance – Product Development Milestones 34
Featured News & Press Releases 34
Jun 11, 2012: Sanofi Announces Results From ORIGIN Clinical Trial In Pre- And Early Diabetes 34
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 35
Sep 16, 2011: Data From QNEXA Sequel Study Featured At 47th EASD Annual Meeting 36
Sep 06, 2011: GENFIT Publishes GFT505 Clinical Trial Results In Diabetes Care 37
Aug 19, 2010: Limerick BioPharma Announces Positive Phase 1b Data for LIM-0705 in Preventing Toxicities Associated with the Transplant Drug, Tacrolimus. 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Pre-Diabetes/Impaired Glucose Tolerance, H2 2012 7
Products under Development for Pre-Diabetes/Impaired Glucose Tolerance – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Resverlogix Corp., H2 2012 15
Limerick BioPharma, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Drug Profile Updates 30
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Pre-Diabetes/Impaired Glucose Tolerance, H2 2012 7
Products under Development for Pre-Diabetes/Impaired Glucose Tolerance – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos